- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01114061
Evaluation of the Effects of Heating the Vicinity of the Insulin Delivery Site by the InsuPatch Device During Daily Life
Study Overview
Detailed Description
Despite the recent years advance in rapid acting insulin analogues early postprandial hyperglycemia and late post prandial hypoglycemia are still common in insulin treated diabetic patients. It appears that even with these rapid acting insulins there is still a significant delay time and variability in the delay time between the changes in blood glucose levels following the meals and the absorption kinetics of insulin injected subcutaneously. Past studies using regular human insulin have demonstrated that using local stimulation at the injection site can dramatically improve regular insulin kinetics. The assumption was that local stimulation induces local increase in blood perfusion which improves insulin absorption from the injection site.
Following the above Insulin has developed the InsuPatch device. The intended use of the InsuPatch device is to improve insulin delivery into the blood when the insulin is infused using an insulin-infusion pump by controlled heating of the area surrounding the point of infusion.
The InsuPatch device consists of two components:
I) InsuPatch single-use, flat, heating pad with electrical wire which is attached by adhesive to the bottom of the Medtronic MiniMed Quick-set® infusion set. The user attaches the device to the infusion set prior to insertion of the infusion set catheter.
II) The InsuPatch case is used as a case for the Medtronic MiniMed Paradigm insulin infusion pump. The InsuPatch case contains an electronic unit and batteries.
The effect of the device on the pharmacokinetics (PK) and pharmacodynamics (PD) of the injected insulin were tested in Euglycemic clamp and meal tolerance test (MTT) studies. The effect of the device on insulin PK was evaluated by comparing insulin concentration in the meal MTT study with and without operation of the device. The effect of the device on insulin PD was evaluated using Euglycemic clamp protocol with and without operation of the device. The effect of the device on postprandial glucose excursions was tested by comparing the post meal glucose levels with and without operation of the device.
The main results of the study were:
- An increase of 49% in the available insulin in the blood during the first 30 minutes post injection and 37% in during the first hour post injection (PK).
- A reduction of 25% in the average glucose level during post-meal first two hours (PD).
- A reduction of 43% in the time to peak action of insulin (PD).
The aim of this study is to test the performance of the InsuPatch device in daily life. The primary target of the study is to evaluate safety aspect of daily device use. Additional aspects to be evaluated in the study are: the effect of the device on post prandial glucose level.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant age between 18- 65 years old (including = 18 years and =65 years)
- BMI: 18-35 kg/m2
- Insulin dependent diabetes under insulin pumps.
- Use of short-acting insulin analogues
- Subjects agreeing to use the InsuPatch device.
- 6% ≤ HbA1c ≤ 9.5%
- Agree to sign consent form.
- Subject is willing to do at least 4 blood glucose recordings per day
- Subject understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed
- Willing to comply with all specified follow-up evaluations
Exclusion Criteria:
- Pregnancy
- Breast feeding women.
- Alcohol addiction
- Had CABG (Coronary Artery Bypass Graft), Post MI (Myocardial Infarction) or had active Ischemic heart disease in the last 3 months prior to the study date
- Had CVA (cardiovascular accident) or TIA (transient ischemic accident) in the last 12 months prior to the study
- Suffer from Hypertension (blood pressure > 140/90) .
- Low blood hemoglobin concentration <9 g/dL for female and <11g/dL for male.
- Known gastro- or enteroparesis
- Abnormal kidney and/ or liver function tests. (Creatinine >1.5 mg/dL, liver test> 2 times the upper limit of the normal range).
- Severe hypoglycemic events requiring glucagon injection or glucose infusion within the last six months prior to study inclusion
- Hypoglycaemia unawareness
- Diabetic ketoacidosis (severe, with hospitalization) within the last six months prior to study inclusion
- Psychological incompetence
- Signs of drug abuse
- Any other clinical condition or history, that seems to be relevant to the principle investigator to disqualify the participant.
- Not willing to sign the inform consent form.
- Subjects with diminished skin integrity, Excessive fibrosis, lipo-hypertrophy or eczema at infusion sites
- Subjects with heat sensitivity
- Subjects involved in or planed to participate in other studies.
- Any subject whom the primary researcher consider not suited to the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: InsuPatch
The arm with the treatment: using the insupatch device to heat the insulin infusion site.
|
Applying heat to the infusion site using the insupatch device
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
show no increase in hypoglycemia events when the InsuPatch device is used compared to the number of hypoglycemia events when the InsuPatch device is not used.
Time Frame: three month with the device and three months without the device
|
Show that the hypoglycemia rate is not increased when the InsuPatch device is used
|
three month with the device and three months without the device
|
Collaborators and Investigators
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- HT4813
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
Clinical Trials on Insupatch
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminatedType 1 DiabetesUnited States
-
Insuline Medical Ltd.CompletedDiabetes Mellitus, Insulin-DependentIsrael, United States
-
Insuline Medical Ltd.Completed
-
Insuline Medical Ltd.CompletedDiabetes Mellitus, Type 1Israel, United States
-
Yale UniversityCompletedType 1 DiabetesUnited States